NASDAQ:OBSV ObsEva - OBSV Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ObsEva SA Please log in to your account or sign up in order to add this asset to your watchlist. $0.12 -0.01 (-7.78%) (As of 03/20/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.12▼$0.1350-Day Range$0.08▼$0.2352-Week Range$0.08▼$2.14Volume2.74 million shsAverage Volume22.99 million shsMarket Capitalization$9.24 millionP/E RatioN/ADividend YieldN/APrice Target$8.40 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media ObsEva MarketRank™ ForecastAnalyst RatingHold2.40 Rating ScoreUpside/Downside6,988.6% Upside$8.40 Price TargetShort InterestHealthy1.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.13Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.95 out of 5 stars 3.2 Analyst's Opinion Consensus RatingObsEva has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.40, ObsEva has a forecasted upside of 6,988.6% from its current price of $0.12.Amount of Analyst CoverageObsEva has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.73% of the float of ObsEva has been sold short.Short Interest Ratio / Days to CoverObsEva has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ObsEva has recently increased by 50.92%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldObsEva does not currently pay a dividend.Dividend GrowthObsEva does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OBSV. Previous Next 2.9 News and Social Media Coverage News SentimentObsEva has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ObsEva this week, compared to 2 articles on an average week.Search Interest83 people have searched for OBSV on MarketBeat in the last 30 days. This is an increase of 219% compared to the previous 30 days.MarketBeat Follows25 people have added ObsEva to their MarketBeat watchlist in the last 30 days. This is an increase of 317% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ObsEva insiders have not sold or bought any company stock.Percentage Held by Insiders14.40% of the stock of ObsEva is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 17.52% of the stock of ObsEva is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of ObsEva is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ObsEva is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioObsEva has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ObsEva (NASDAQ:OBSV) StockObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.Read More Receive OBSV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ObsEva and its competitors with MarketBeat's FREE daily newsletter. Email Address OBSV Stock News HeadlinesMarch 20, 2023 | americanbankingnews.comObsEva SA (NASDAQ:OBSV) Receives $8.33 Average Price Target from BrokeragesMarch 19, 2023 | americanbankingnews.comObsEva (NASDAQ:OBSV) Coverage Initiated at StockNews.comMarch 21, 2023 | Health Sector Insight (Ad)Penny Stock Shows Big PotentialThe $4.37 trillion wellness market and the little-known penny stock to get on radar now. March 15, 2023 | finance.yahoo.comObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023March 13, 2023 | markets.businessinsider.comObsEva Names Fabien De Ladonchamps CEO, Ernest Loumaye Interim ChairmanMarch 13, 2023 | finance.yahoo.comObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in SwitzerlandMarch 12, 2023 | americanbankingnews.comStockNews.com Begins Coverage on ObsEva (NASDAQ:OBSV)March 3, 2023 | benzinga.comWhy Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day SessionMarch 21, 2023 | Health Sector Insight (Ad)Penny Stock Shows Big PotentialThe $4.37 trillion wellness market and the little-known penny stock to get on radar now. March 3, 2023 | investorplace.comWhy Is ObsEva (OBSV) Stock Up 93% Today?February 24, 2023 | investorplace.comWhy ObsEva (OBSV) Stock Is Down 36% TodayFebruary 24, 2023 | finance.yahoo.comObsEva Announces Strategic Reorganization to Consolidate Operations in SwitzerlandJanuary 12, 2023 | uk.finance.yahoo.comObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request FilingDecember 19, 2022 | finance.yahoo.comObsEva Announces Dismissal of Moratorium ProceedingsDecember 14, 2022 | finance.yahoo.comObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request FilingDecember 1, 2022 | finance.yahoo.comObsEva SA (OBSV) Reports Q3 Loss, Lags Revenue EstimatesDecember 1, 2022 | finance.yahoo.comObsEva Announces Third Quarter 2022 Financial Results and Provides a Business UpdateOctober 27, 2022 | finance.yahoo.comObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium ProceedingsOctober 16, 2022 | finance.yahoo.comObsEva SA (OBSV)October 14, 2022 | markets.businessinsider.comObsEva : China Approves Yuyuan Bioscience's IND Application For Phase 1 Trial Of NolasibanOctober 13, 2022 | finance.yahoo.comObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China - Yahoo FinanceOctober 13, 2022 | benzinga.comObsEva Announces IND Approval for Yuyuan Bioscience's Phase 1 Clinical Trial of Nolasiban in China - ObsE - BenzingaOctober 13, 2022 | globenewswire.comObsEva Announces IND Approval for Yuyuan Bioscience's Phase - GlobeNewswireOctober 13, 2022 | finance.yahoo.comObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in ChinaOctober 6, 2022 | reuters.comOBSV.PH - Obseva SA | Stock Price & Latest News | ReutersSeptember 15, 2022 | baystreet.caObsEva Flat on Restructuring Initiatives - Baystreet.caSeptember 13, 2022 | finance.yahoo.comAfter FDA Regulatory Setback, Penny Stock ObsEva Cuts 70% Of Its StaffSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive OBSV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ObsEva and its competitors with MarketBeat's FREE daily newsletter. Email Address OBSV Company Calendar Last Earnings11/04/2021Today3/20/2023Next Earnings (Estimated)3/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OBSV CUSIPN/A CIK1685316 Webwww.obseva.com Phone(122) 552-3840FaxN/AEmployees48Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.40 High Stock Price Forecast$12.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+6,988.6%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,380,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-416.36% Return on Assets-92.01% Debt Debt-to-Equity RatioN/A Current Ratio0.61 Quick Ratio0.61 Sales & Book Value Annual Sales$20.11 million Price / Sales0.46 Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book0.29Miscellaneous Outstanding Shares77,970,000Free Float66,743,000Market Cap$9.24 million OptionableNot Optionable Beta0.68 Key ExecutivesWilliam M. BrownChief Executive & Financial OfficerElke BestelVP, Head-Drug Safety & PharmacovigilanceKatja BuhrerChief Strategy OfficerKey CompetitorsVascular BiogenicsNASDAQ:VBLTNexImmuneNASDAQ:NEXILandos BiopharmaNASDAQ:LABPAlterity TherapeuticsNASDAQ:ATHEImunonNASDAQ:IMNNView All CompetitorsInstitutional OwnershipCredit Suisse AGBought 173,455 shares on 2/13/2023Ownership: 2.245%Simplex Trading LLCSold 4,100 shares on 2/2/2023Ownership: 0.000%View All Institutional Transactions OBSV Stock - Frequently Asked Questions Should I buy or sell ObsEva stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ObsEva in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OBSV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OBSV, but not buy additional shares or sell existing shares. View OBSV analyst ratings or view top-rated stocks. What is ObsEva's stock price forecast for 2023? 5 equities research analysts have issued 1 year price targets for ObsEva's shares. Their OBSV share price forecasts range from $1.00 to $12.00. On average, they anticipate the company's stock price to reach $8.40 in the next year. This suggests a possible upside of 6,988.6% from the stock's current price. View analysts price targets for OBSV or view top-rated stocks among Wall Street analysts. How have OBSV shares performed in 2023? ObsEva's stock was trading at $0.1450 on January 1st, 2023. Since then, OBSV shares have decreased by 18.3% and is now trading at $0.1185. View the best growth stocks for 2023 here. Are investors shorting ObsEva? ObsEva saw a increase in short interest in February. As of February 28th, there was short interest totaling 719,300 shares, an increase of 50.9% from the February 13th total of 476,600 shares. Based on an average daily trading volume, of 7,080,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 1.7% of the shares of the company are sold short. View ObsEva's Short Interest. When is ObsEva's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023. View our OBSV earnings forecast. How were ObsEva's earnings last quarter? ObsEva SA (NASDAQ:OBSV) posted its earnings results on Thursday, November, 4th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.23. What other stocks do shareholders of ObsEva own? Based on aggregate information from My MarketBeat watchlists, some companies that other ObsEva investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN), Zosano Pharma (ZSAN), Vaxart (VXRT), VBI Vaccines (VBIV), Bionano Genomics (BNGO) and ADMA Biologics (ADMA). When did ObsEva IPO? (OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO. What is ObsEva's stock symbol? ObsEva trades on the NASDAQ under the ticker symbol "OBSV." Who are ObsEva's major shareholders? ObsEva's stock is owned by many different retail and institutional investors. Top institutional investors include Credit Suisse AG (2.25%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of ObsEva? Shares of OBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ObsEva's stock price today? One share of OBSV stock can currently be purchased for approximately $0.12. How much money does ObsEva make? ObsEva (NASDAQ:OBSV) has a market capitalization of $9.24 million and generates $20.11 million in revenue each year. The company earns $-58,380,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis. How can I contact ObsEva? ObsEva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The official website for the company is www.obseva.com. The company can be reached via phone at (122) 552-3840 or via email at ir@obseva.ch. This page (NASDAQ:OBSV) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.